IP Library › Granted Patent US 12,318,482
Granted Patent B2
US 12,318,482 · App. 18/214,335 · Granted Jun 3, 2025

Exosomal compositions and methods for the treatment of disease

Inventor: Huang-Ge Zhang (Louisville, KY)
Assignee: University of Louisville Research Foundation, Inc.
A61K9/127A61K31/05A61K31/12A61K31/282A61K31/337A61K31/353A61K31/475A61K31/513A61K31/575A61K31/704A61K33/243A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,482
App. No.
18/214,335
Granted
Jun 3, 2025
Kind
B2
Abstract

An exosomal composition is provided that includes a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions that contain the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.

Claims (13)

1. A method of delivering a therapeutic agent to a mammal, the method comprising administering to the mammal an exosomal composition comprising a therapeutic agent encapsulated by an isolated exosome derived from a plant; wherein the exosome is isolated from the juice of a fruit of the plant.

2. The method of claim 1 , wherein the therapeutic agent is a phytochemical agent.

3. The method of claim 2 , wherein the phytochemical agent is selected from the group consisting of curcumin, resveratrol, baicalein, equol, fisetin, and quercetin.

4. The method of claim 1 , wherein the therapeutic agent is a chemotherapeutic agent.

5. The method of claim 4 , wherein the chemotherapeutic agent is selected from the group consisting of retinoic acid, 5-fluorouracil, vincristine, actinomycin D, cisplatin, docetaxel, doxorubicin, and paclitaxel.

6. The method of claim 1 , wherein the therapeutic agent is a Stat3 inhibitor.

7. The method of claim 1 , wherein the therapeutic agent is an siRNA.

8. The method of claim 1 , wherein the therapeutic agent is a microRNA.

9. The method of claim 1 , wherein the exosomal composition binds to a target cell or tissue.

10. The method of claim 1 , wherein the exosomal composition further comprises a pharmaceutically-acceptable vehicle, carrier, or excipient.

11. The method of claim 1 , wherein the exosomal composition is formulated for intranasal, oral, or intratumoral administration.

12. The method of claim 1 , wherein the exosomal composition is administered intranasally.

13. The method of claim 1 , wherein the exosomal composition is administered orally.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2025
From: ZHANG, HUANG-GE
To: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
Reel/Frame 070142/0499 →
Continuity (8)
Continuation 18129593 · Mar 31, 2023
Continuation 16359618 · Mar 20, 2019
Continuation 15917151 · Mar 9, 2018
Continuation 14107691 · Dec 16, 2013
Continuation 13576907
Provisional Application 61424875 · Dec 20, 2010
Provisional Application 61301939 · Feb 5, 2010
Related Publication 20230355525A1 · Nov 9, 2023
References Cited (7)
US 20090299045A1 · Richards et al. · 2009 [cited by applicant]
WO WO2005004925A1 · 2005 [cited by examiner]
WO 2007126386A1 · 2007 [cited by applicant]
Regente, M. et al. 2009. Vesicular fractions of sunflower apoplastic fluids are associated with potential exosome marker proteins. FEBS Letters 583: 3363-3366; specif. pp. 3363, 3364, 3365, 3366 (Year: 2009). [cited by examiner]
Jacob, J.K. et al. 2008. Physico-chemical characteristics of nanovesicle-carbohydrate complexes in grape juice concentrate. Journal of Agricultural and Food Chemistry 56: 1305-1315; specif. pp. 1305, 1306, 1312, 1314 (Y… [cited by examiner]
Non-Final Office Action received in connection with U.S. Appl. No. 18/129,593, dated May 24, 2024, 26 pages. [cited by applicant]
Kim, S.H. et al. 2007. Effective treatment of inflammatory diesease models with exosomes derived from dendritic cells genetically modified to express IL-4. Journal of Immunology 179: 2242-2249; specif. pp. 2242, 2243, 2… [cited by applicant]